Suppression of skin lesions and SLE nephritis by increasing Treg in MRL/FAS lpr mice by administration of bee venom Apitoxin®
Abstract Background Apitoxin®, a drug based on bee venom was approved and released in Korea in 2003 as the ethical drug (ETC). It is well-known for its pain-relieving properties due to its potent anti-inflammatory effects. This raises the question of whether bee venom has benefits for other inflamma...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-03-01
|
| Series: | Advances in Rheumatology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s42358-025-00448-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|